EU authorizes Komboglyze and widens approval of Onglyza

11/29/2011 | PharmaTimes (U.K.)

Bristol-Myers Squibb and AstraZeneca secured expanded approval from the European Commission to promote Onglyza in combination with insulin for adults with type 2 diabetes. The commission also approved type 2 diabetes medicine Komboglyze, a daily tablet that comprises Onglyza and standard drug metformin.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs: